To Compare the Efficacy and Safety of Tripterygium (TW) Versus Valsartan in the Diabetic Nephropathy (DN)

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and safety of Tripterygium (TW) versus Valsartan (ARB) in the Diabetic Nephropathy (DN).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing University School of Medicine
• Treatments: Valsartan

Criteria

Inclusion Criteria:

1. A new diagnosis of diabetic nephropathy proved by histology and(or) serology.

2. Proteinuria > 2.5 g/24 h

3. serum creatinine < 3 mg/dl

4. age 35-65 years

Exclusion Criteria:

1. Co-existence of anther chronic glomerular nephritis.

2. Severe disfunction of the liver

3. White blood cell < 3000/ul

4. Severe infection in the past 1 month

5. Malignant hypertension which in hard to control

6. Myocardial infarct or heart failure or sever cerebral vessels complication in the past 6 month